Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer (Q39583104)

13 September 2017

Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer (English)

1 reference

13 September 2017

0 references

1 reference

Karl-Hermann Schlingensiepen

1

1 reference

13 September 2017

Frank Jaschinski

2

1 reference

13 September 2017

Sven Arke Lang

3

1 reference

13 September 2017

Christian Moser

4

1 reference

13 September 2017

Edward Kenneth Geissler

5

1 reference

13 September 2017

Hans Jürgen Schlitt

6

1 reference

13 September 2017

Marcus Kielmanowicz

7

1 reference

13 September 2017

Anneliese Schneider

8

1 reference

13 September 2017

30 March 2011

1 reference

13 September 2017

1 reference

13 September 2017

102

1 reference

13 September 2017

6

1 reference

13 September 2017

1193-1200

1 reference

13 September 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Locally advanced pancreatic cancer: current therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Novel clinical strategies for the treatment of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Basics of TGF-beta and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

TGF-beta signaling: positive and negative effects on tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Transforming growth factor-beta signaling and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces or

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Characterization of oligonucleotide transport into living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Identification and characterization of a cell membrane nucleic acid channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

In situ entry of oligonucleotides into brain cells can occur through a nucleic acid channel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

RNA learns from antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Concepts in in vivo siRNA delivery for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Role of transforming growth factor Beta in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Roles of TGFbeta in metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

TGF-beta-based immunotherapy for cancer: breaching the tumor firewall

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.01917.X

10.1111/J.1349-7006.2011.01917.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference